Prostate cancer is the primary cancer in males, with increasing global incidence rates making this malignancy a significant healthcare burden. Androgens not only promote normal prostate maturity but also influence the development and progression of prostate cancer. Intriguingly, evidence now suggests endogenous and exogenous oestrogens, in the form of phytoestrogens, may be equally as relevant as androgens in prostate cancer growth. The prostate gland has the molecular mechanisms, catalysed by steroid sulphatase (STS), to unconjugate and utilise circulating oestrogens. Furthermore, prostate tissue also expresses enzymes essential for local oestrogen metabolism, including aromatase (CYP19A1) and 3β- and 17β-hydroxysteroid dehydrogenases. Increased expression of these enzymes in malignant prostate tissue compared with normal prostate indicates that oestrogen synthesis is favoured in malignancy and thus may influence tumour progression. In contrast to previous reviews, here we comprehensively explore the epidemiological and scientific evidence on how oestrogens impact prostate cancer, particularly focusing on pre-receptor oestrogen metabolism and subsequent molecular action. We analyse how molecular mechanisms and metabolic pathways involved in androgen and oestrogen synthesis intertwine to alter prostate tissue. Furthermore, we speculate on whether oestrogen receptor status in the prostate affects progression of this malignancy.
Endocrine-Related Cancer is committed to supporting researchers in demonstrating the impact of their articles published in the journal.
The two types of article metrics we measure are (i) more traditional full-text views and pdf downloads, and (ii) Altmetric data, which shows the wider impact of articles in a range of non-traditional sources, such as social media.
More information is on the Reasons to publish page.
Sept 2018 onwards | Past Year | Past 30 Days | |
---|---|---|---|
Full Text Views | 31 | 10 | 0 |
PDF Downloads | 24 | 9 | 0 |
Acconcia F, Totta P, Ogawa S, Cardillo I, Inoue S, Leone S, Trentalance A, Muramatsu M & Marino M 2005 Survival versus apoptotic 17β-estradiol effect: role of ERα and ERβ activated non-genomic signaling. Journal of Cellular Physiology 203 193–201. (doi:10.1002/jcp.20219)
Adams KF, Chen C, Newton KM, Potter JD & Lampe JW 2004 Soy isoflavones do not modulate prostate-specific antigen concentrations in older men in a randomized controlled trial. Cancer Epidemiology Biomarkers & Prevention 13 644–648.
Adeniji AO, Chen M & Penning TM 2013 AKR1C3 as a target in castrate resistant prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 137 136–149. (doi:10.1016/j.jsbmb.2013.05.012)
Adlercreutz H, Mazur W, Bartels P, Elomaa V-V, Watanabe S, Wähälä K, Landström M, Lundin E, Bergh A, Damber J-E, et al.2000 Phytoestrogens and prostate disease. Journal of Nutrition 130 658.
Allen NE, Appleby PN, Davey GK & Key TJ 2002 Lifestyle and nutritional determinants of bioavailable androgens and related hormones in British men. Cancer Causes & Control 13 353–363.
Allott EH, Masko EM & Freedland SJ 2013 Obesity and prostate cancer: weighing the evidence. European Urology 63 800–809. (doi:10.1016/j.eururo.2012.11.013)
Barazani Y, Katz BF, Nagler HM & Stember DS 2014 Lifestyle, environment, and male reproductive health. Urologic Clinics of North America 41 55–66. (doi:10.1016/j.ucl.2013.08.017)
Barzi A, Lenz AM, Labonte MJ & Lenz H-J 2013 Molecular pathways: estrogen pathway in colorectal cancer. Clinical Cancer Research 19 5842–5848. (doi:10.1158/1078-0432.CCR-1113-0325)
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, et al.2014 Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine 371 424–433. (doi:10.1056/NEJMoa1405095)
Bhatt S, Xiao Z, Meng Z & Katzenellenbogen BS 2012 Phosphorylation by p38 mitogen-activated protein kinase promotes estrogen receptorαturnover and functional activity via the SCF(Skp2) proteasomal complex. Molecular and Cellular Biology 32 1928–1943. (doi:10.1128/MCB.06561-11)
Block JL, Block NL & Lokeshwar BL 1996 Modulation of aromatase activity by growth factors in an androgen sensitive human prostate cancer cell line, LNCaP. Cancer Letters 102 167–172. (doi:10.1016/0304-3835(96)04176-6)
Bosset P-O, Albiges L, Seisen T, de la Motte Rouge T, Phé V, Bitker M-O & Rouprêt M 2012 Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU International 110 E826–E829. (doi:10.1111/j.1464-410X.2012.11206.x)
Brooke GN & Bevan CL 2009 The role of androgen receptor mutations in prostate cancer progression. Current Genomics 10 18–25. (doi:10.2174/138920209787581307)
Bulun SE, Economos K, Miller D & Simpson ER 1994 CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. Journal of Clinical Endocrinology & Metabolism 79 1831–1834. (doi:10.1210/jcem.79.6.7989490)
Burns KA & Korach KS 2012 Estrogen receptors and human disease: an update. Archives of Toxicology 86 1491–1504. (doi:10.1007/s00204-012-0868-5)
Buxhofer-Ausch V, Secky L, Wlcek K, Svoboda M, Kounnis V, Briasoulis E, Tzakos AG, Jaeger W & Thalhammer T 2013 Tumor-specific expression of organic anion-transporting polypeptides: transporters as novel targets for cancer therapy. Journal of Drug Delivery 2013 863539. (doi:10.1155/2013/863539)
Capper CP, Larios JM, Sikora MJ, Johnson MD & Rae JM 2016 The CYP17A1 inhibitor abiraterone exhibits estrogen receptor agonist activity in breast cancer. Breast Cancer Research and Treatment 1–8. (doi:10.1007/s10549-016-3774-3)
Center MM, Jemal A, Lortet-Tieulent J, Ward E, Ferlay J, Brawley O & Bray F 2012 International variation in prostate cancer incidence and mortality rates. European Urology 61 1079–1092. (doi:10.1016/j.eururo.2012.02.054)
Chan QK, Lam H-M, Ng C-F, Lee AY, Chan ES, Ng H-K, Ho S-M & Lau K-M 2010 Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G2 cell-cycle arrest. Cell Death & Differentiation 17 1511–1523. (doi:10.1038/cdd.2010.20)
Chang K-H, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ & Sharifi N 2011 Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. PNAS 108 13728–13733. (doi:10.1073/pnas.1107898108)
Chen S 1998 Aromatase and breast cancer. Frontiers in Bioscience: A Journal and Virtual Library 3 d922–d933.
Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG & Sawyers CL 2004 Molecular determinants of resistance to antiandrogen therapy. Nature Medicine 10 33–39. (doi:10.1038/nm972)
Chen M, Ni J, Chang H-C, Lin C-Y, Muyan M & Yeh S 2009 CCDC62/ERAP75 functions as a coactivator to enhance estrogen receptor beta-mediated transactivation and target gene expression in prostate cancer cells. Carcinogenesis 30 841–850. (doi:10.1093/carcin/bgn288)
Chen M, Yeh C-R, Chang H-C, Vitkus S, Wen X-Q, Bhowmick NA, Wolfe A & Yeh S 2012 Loss of epithelial oestrogen receptorαinhibits oestrogen-stimulated prostate proliferation and squamous metaplasia via in vivo tissue selective knockout models. Journal of Pathology 226 17–27. (doi:10.1002/path.2949)
Chevalier N, Bouskine A & Fenichel P 2011 Role of GPER/GPR30 in tumoral testicular germ cells proliferation. Cancer Biology & Therapy 12 2–3. (doi:10.4161/cbt.12.1.15726)
Christoforou P, Christopoulos PF & Koutsilieris M 2014 The role of estrogen receptor β in prostate cancer. Molecular Medicine 20 427–434. (doi:10.2119/molmed.2014.00105)
Claessens F, Helsen C, Prekovic S, Van den Broeck T, Spans L, Van Poppel H & Joniau S 2014 Emerging mechanisms of enzalutamide resistance in prostate cancer. Nature Reviews. Urology 11 712–716. (doi:10.1038/nrurol.2014.243)
Clemons J, Glodé LM, Gao D & Flaig TW 2013 Low-dose diethylstilbestrol for the treatment of advanced prostate cancer. Urologic Oncology: Seminars and Original Investigations 31 198–204. (doi:10.1016/j.urolonc.2010.12.004)
Cook LS, Goldoft M, Schwartz SM & Weiss NS 1999 Incidence of adenocarcinoma of the prostate in asian immigrants to the United States and their descendants. Journal of Urology 161 152–155. (doi:10.1016/S0022-5347(01)62086-X)
Cui J, Shen Y & Li R 2013 Estrogen synthesis and signaling pathways during ageing: from periphery to brain. Trends in Molecular Medicine 19 197–209. (doi:10.1016/j.molmed.2012.12.007)
Cunha GR 1994 Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer 74 1030–1044. (doi:10.1002/1097-0142(19940801)74:3+<1030::aid-cncr2820741510>3.0.co;2-q)
Da J, Lu M & Wang Z 2015 Estrogen receptor alpha (ERα)-associated fibroblasts promote cell growth in prostate cancer. Cell Biochemistry and Biophysics 73 793–798. (doi:10.1007/s12013-015-0700-y)
Daniels NA, Nielson CM, Hoffman AR & Bauer DC 2010 Sex hormones and the risk of incident prostate cancer. Urology 76 1034–1040. (doi:10.1016/j.urology.2010.01.086)
Davies JH, Dowsett M, Jacobs S, Coombes RC, Hedley A & Shearer RJ 1992 Aromatase inhibition: 4-hydroxyandrostenedione (4-OHA, CGP 32349) in advanced prostatic cancer. British Journal of Cancer 66 139–142. (doi:10.1038/bjc.1992.231)
Day JM, Foster PA, Tutill HJ, Schmidlin F, Sharland CM, Hargrave JD, Vicker N, Potter BVL, Reed MJ & Purohit A 2013 STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model. Endocrine-Related Cancer 20 53–64. (doi:10.1530/ERC-12-0231)
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OBJ, Saad F, et al.2011 Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine 364 1995–2005. (doi:10.1056/NEJMoa1014618)
De Nunzio C, Albisinni S, Freedland SJ, Miano L, Cindolo L, Finazzi Agrò E, Autorino R, De Sio M, Schips L & Tubaro A 2013 Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: a prospective multicenter Italian cohort study. Urologic Oncology: Seminars and Original Investigations 31 997–1002. (doi:10.1016/j.urolonc.2011.08.007)
Deblois G & Giguere V 2013 Oestrogen-related receptors in breast cancer: control of cellular metabolism and beyond. Nature Reviews. Cancer 13 27–36. (doi:10.1038/nrc3396)
deVere White RW, Hackman RM, Soares SE, Beckett LA, Li Y & Sun B 2004 Effects of a genistein-rich extract on PSA levels in men with a history of prostate cancer. Urology 63 259–263. (doi:10.1016/j.urology.2003.09.061)
Dey P, Strom A & Gustafsson JA 2014 Estrogen receptor [beta] upregulates FOXO3a and causes induction of apoptosis through PUMA in prostate cancer. Oncogene 33 4213–4225. (doi:10.1038/onc.2013.384)
Di Zazzo E, Galasso G, Giovannelli P, Di Donato M, Di Santi A, Cernera G, Rossi V, Abbondanza C, Moncharmont B, Sinisi AA, et al.2016 Prostate cancer stem cells: the role of androgen and estrogen receptors. Oncotarget 7 193–208. (doi:10.18632/oncotarget.6220)
Ellem SJ & Risbridger GP 2007 Treating prostate cancer: a rationale for targeting local oestrogens. Nature Reviews. Cancer 7 621–627. (doi:10.1038/nrc2174)
Ellem SJ & Risbridger GP 2009 The dual, opposing roles of estrogen in the prostate. Annals of the New York Academy of Sciences 1155 174–186. (doi:10.1111/j.1749-6632.2009.04360.x)
Ellem SJ & Risbridger GP 2010 Aromatase and regulating the estrogen: androgenratio in the prostate gland. Journal of Steroid Biochemistry and Molecular Biology 118 246–251. (doi:10.1016/j.jsbmb.2009.10.015)
Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M & Risbridger GP 2004 Local aromatase expression in human prostate is altered in malignancy. Journal of Clinical Endocrinology & Metabolism 89 2434–2441. (doi:10.1210/jc.2003-030933)
Evaul K, Li R, Papari-Zareei M, Auchus RJ & Sharifi N 2010 3β-Hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. Endocrinology 151 3514–3520. (doi:10.1210/en.2010-0138)
Farnsworth WE 1973 Human prostatic dehydroepiandrosterone sulfate sulfatase. Steroids 21 647–664. (doi:10.1016/0039-128X(73)90134-7)
Foster PA 2013 Oestrogen and colorectal cancer: mechanisms and controversies. International Journal of Colorectal Disease 28 737–749. (doi:10.1007/s00384-012-1628-y)
Foster PA, Newman SP, Chander SK, Stengel C, Jhalli R, Woo LL, Potter BV, Reed MJ & Purohit A 2006 In vivo efficacy of STX213, a second-gegneration steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. Clinical Cancer Research 12 5543–5549. (doi:10.1158/1078-0432.CCR-06-0632)
Foster PA, Chander SK, Parsons MF, Newman SP, Woo LW, Potter BV, Reed MJ & Purohit A 2008 Efficacy of three potent steroid sulfatase inhibitors: pre-clinical investigations for their use in the treatment of hormone-dependent breast cancer. Breast Cancer Research and Treatment 111 129–38. (doi:10.1007/s10549-007-9769-3)
Francis JC, Thomsen MK, Taketo MM & Swain A 2013 β-catenin is required for prostate development and cooperates with Pten loss to drive invasive carcinoma. PLoS Genetics 9 e1003180.
Fu C, Dong W-Q, Wang A & Qiu G 2014 The influence of ESR1 rs9340799 and ESR2 rs1256049 polymorphisms on prostate cancer risk. Tumor Biology 35 8319–8328. (doi:10.1007/s13277-014-2086-7)
Gautier A, Bonnet F, Dubois S, Massart C, Grosheny C, Bachelot A, Aubé C, Balkau B & Ducluzeau P-H 2013 Associations between visceral adipose tissue, inflammation and sex steroid concentrations in men. Clinical Endocrinology 78 373–378. (doi:10.1111/j.1365-2265.2012.04401.x)
Geier R, Adler S, Rashid G & Klein A 2010 The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells. Prostate 70 1307–1312. (doi:10.1002/pros.21166)
Giton F, Sirab N, Franck G, Gervais M, Schmidlin F, Ali T, Allory Y, Taille Adl, Vacherot F, Loric S, et al.2015 Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostate. Journal of Steroid Biochemistry and Molecular Biology 152 89–100. (doi:10.1016/j.jsbmb.2015.05.002)
Goetzl MA, VanVeldhuizen PJ & Thrasher JB 2007 Effects of soy phytoestrogens on the prostate. Prostate Cancer and Prostatic Diseases 10 216–223. (doi:10.1038/sj.pcan.4500953)
Gooren L & Morgentaler A 2014 Prostate cancer incidence in orchidectomised male-to-female transsexual persons treated with oestrogens. Andrologia 46 1156–1160. (doi:10.1111/and.12208)
Grönberg H 2003 Prostate cancer epidemiology. Lancet 361 859–864. (doi:10.1016/S0140-6736(03)12713-4)
Hanahan D & Weinberg Robert A 2011 Hallmarks of cancer: the next generation. Cell 144 646–674. (doi:10.1016/j.cell.2011.02.013)
Hariri W, Sudha T, Bharali DJ, Cui H & Mousa SA 2015 Nano-targeted delivery of toremifene, an estrogen receptor-α blocker in prostate cancer. Pharmaceutical Research 32 2764–2774.
Härkönen PL & Mäkelä SI 2004 Role of estrogens in development of prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 92 297–305. (doi:10.1016/j.jsbmb.2004.10.016)
Henderson BE, Bernstein L, Ross RK, Depue RH & Judd HL 1988 The early in utero oestrogen and testosterone environment of blacks and whites: potential effects on male offspring. British Journal of Cancer 57 216–218. (doi:10.1038/bjc.1988.46)
Ho S-M 2004 Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. Journal of Cellular Biochemistry 91 491–503. (doi:10.1002/jcb.10759)
Hofland J, van Weerden WM, Dits NFJ, Steenbergen J, van Leenders GJLH, Jenster G, Schröder FH & de Jong FH 2010 Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Research 70 1256–1264. (doi:10.1158/0008-5472.CAN-09-2092)
Hofland J, Weerden WMv, Steenbergen J, Dits NFJ, Jenster G & Jong FHd 2011 Activin A regulates local testosterone production and growth in prostate cancer through 17β-hydroxysteroid dehydrogenase. In 13th European Congress of Endocrinology, p 353. Rotterdam, The Netherlands: Endocrine Abstracts, Bioscientifica.
Holt SK, Kwon EM, Fu R, Kolb S, Feng Z, Ostrander EA & Stanford JL 2013 Association of variants in estrogen-related pathway genes with prostate cancer risk. Prostate 73 1–10. (doi:10.1002/pros.22534)
Howell MA 1974 Factor analysis of international cancer mortality data and per capita food consumption. British Journal of Cancer 29 328–336. (doi:10.1038/bjc.1974.75)
Huang W, Chen Y, Liu Y, Zhang Q, Yu Z, Mou L, Wu H, Zhao L, Long T, Qin D, et al.2015 Roles of ERβ and GPR30 in proliferative response of human bladder cancer cell to estrogen. BioMed Research International 2015 251780.
Huggins C & Hodges CV 1941 Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research 1 293–297.
Hussain S, Lawrence MG, Taylor RA, Lo CY-W, BioResource APC, Frydenberg M, Ellem SJ, Furic L & Risbridger GP 2012 Estrogen receptorβactivation impairs prostatic regeneration by inducing apoptosis in murine and human stem/progenitor enriched cell populations. PLoS ONE 7 e40732.
Jacob M & Henrik M 2006 One, five and ten year cancer prevalence by Cancer Network, UK, 2006. In One, Five and Ten Year Cancer Prevalence by Cancer Network, UK. London, UK: National Cancer Intelligence Network.
Jasuja GK, Travison TG, Davda M, Murabito JM, Basaria S, Zhang A, Kushnir MM, Rockwood AL, Meikle W, Pencina MJ, et al.2013 Age trends in estradiol and estrone levels measured using liquid chromatography tandem mass spectrometry in community-dwelling men of the framingham heart study. Journals of Gerontology Series A: Biological Sciences and Medical Sciences 68 733–740. (doi:10.1093/gerona/gls216)
Jurečeková J, Babušíková E, Kmeťová M, Kliment J & Dobrota D 2015 Estrogen receptor alpha polymorphisms and the risk of prostate cancer development. Journal of Cancer Research and Clinical Oncology 141 1963–1971. (doi:10.1007/s00432-015-1966-6)
Khurana I 2008 Essentials of Medical Physiology. New Delhi, India: Elsevier India Pvt. Limited.
Kimbro K & Simons J 2006 Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocrine-Related Cancer 13 739–749. (doi:10.1677/erc.1.00728)
King KJ, Nicholson HD & Assinder SJ 2006 Effect of increasing ratio of estrogen: androgen on proliferation of normal human prostate stromal and epithelial cells, and the malignant cell line LNCaP. Prostate 66 105–114. (doi:10.1002/pros.20327)
Klein H, Molwitz T & Bartsch W 1989 Steroid sulfate sulfatase in human benign prostatic hyperplasia: characterization and quantification of the enzyme in epithelium and stroma. Journal of Steroid Biochemistry 33 195–200. (doi:10.1016/0022-4731(89)90294-X)
Knochenhauer ES, Boots LR, Potter HD & Azziz R 1998 Differential binding of estradiol and testosterone to SHBG. Relation to circulating estradiol levels. Journal of Reproductive Medicine 43 665–670.
Koh E, Noda T, Kanaya J & Namiki M 2002 Differential expression of 17β2010hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 53 154–159. (doi:10.1002/pros.10139)
Kolonel LN, Altshuler D & Henderson BE 2004 The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nature Reviews. Cancer 4 519–527. (doi:10.1038/nrc1389)
Kuiper GGJM, Lemmen JG, Carlsson B, Corton JC, Safe SH, Saag PTvd, Burg Bvd & Gustafsson J-Å 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139 4252–4263. (doi:10.1210/endo.139.10.6216)
Kumagai J, Hofland J, Erkens-Schulze S, Dits NFJ, Steenbergen J, Jenster G, Homma Y, de Jong FH & van Weerden WM 2013 Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis. Prostate 73 1636–1650. (doi:10.1002/pros.22655)
Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J & Candas B 2005 Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocrine Reviews 26 361–379. (doi:10.1210/er.2004-0017)
Lam H-M, Ouyang B, Chen J, Ying J, Wang J, Wu C-L, Jia L, Medvedovic M, Vessella RL & Ho S-M 2014 Targeting GPR30 with G-1: a new therapeutic target for castration-resistant prostate cancer. Endocrine-Related Cancer 21 903–914. (doi:10.1530/ERC-14-0402)
Lee J, Demissie K, Lu S & Rhoads GG 2007 Cancer incidence among Korean-American immigrants in the United States and native Koreans in South Korea. Cancer Control 14 78.
Leung Y-K, Mak P, Hassan S & Ho S-M 2006 Estrogen receptor (ER)-β isoforms: a key to understanding ER-β signaling. PNAS 103 13162–13167. (doi:10.1073/pnas.0605676103)
Leung Y-K, Lam H-M, Wu S, Song D, Levin L, Cheng L, Wu C-L & Ho S-M 2010 Estrogen receptor β2 and β5 are associated with poor prognosis in prostate cancer, and promote cancer cell migration and invasion. Endocrine-Related Cancer 17 675–689. (doi:10.1677/ERC-09-0294)
Li R, Evaul K, Sharma KK, Chang K-H, Yoshimoto J, Liu J, Auchus RJ & Sharifi N 2012 Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clinical Cancer Research 18 3571–3579. (doi:10.1158/1078-0432.CCR-12-0908)
Li Y, Wu Y, Abbatiello TC, Wu WL, Kim JR, Sarkissyan M, Sarkissyan S, Chung SS, Elshimali Y & Vadgama JV 2015a Slug contributes to cancer progression by direct regulation of ERα signaling pathway. International Journal of Oncology 46 1461–1472.
Li Z, Bishop AC, Alyamani M, Garcia JA, Dreicer R, Bunch D, Liu J, Upadhyay SK, Auchus RJ & Sharifi N 2015b Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 523 347–351. (doi:10.1038/nature14406)
Liu C, Lou W, Zhu Y, Yang JC, Nadiminty N, Gaikwad NW, Evans CP & Gao AC 2015 Intracrine androgens and AKR1C3 activation confer resistance to enzalutamide in prostate cancer. Cancer Research 75 1413–1422. (doi:10.1158/0008-5472.CAN-14-3080)
Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, Wood CA, Ettinger SL, Gleave ME & Nelson CC 2008 Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research 68 6407–6415. (doi:10.1158/0008-5472.CAN-07-5997)
Lukacik P, Kavanagh KL & Oppermann U 2006 Structure and function of human 17β-hydroxysteroid dehydrogenases. Molecular and Cellular Endocrinology 248 61–71. (doi:10.1016/j.mce.2005.12.007)
Luu-The V, Bélanger A & Labrie F 2008 Androgen biosynthetic pathways in the human prostate. Best Practice & Research Clinical Endocrinology & Metabolism 22 207–221. (doi:10.1016/j.beem.2008.01.008)
Maier KG, Brandy K, Kittur D, Kort K & LaSpina M 2006 GPR30: a novel estrogen receptor expressed in aggressive prostate cancer. FASEB Journal 20 A221.
Mak P, Leav I, Pursell B, Bae D, Yang X, Taglienti CA, Gouvin LM, Sharma VM & Mercurio AM 2010 ERβ Impedes prostate cancer EMT by destabilizing HIF-1α and inhibiting VEGF-mediated snail nuclear localization: implications for gleason grading. Cancer Cell 17 319–332. (doi:10.1016/j.ccr.2010.02.030)
Mak P, Li J, Samanta S & Mercurio AM 2015 ERβ regulation of NF-κB activation in prostate cancer is mediated by HIF-1. Oncotarget 6 40247–40254. (doi:10.18632/oncotarget.5377)
Malkowicz SB 2001 The role of diethylstilbestrol in the treatment of prostate cancer. Urology 58 108–113. (doi:10.1016/S0090-4295(01)01252-3)
Marcelli M, Ittmann M, Mariani S, Sutherland R, Nigam R, Murthy L, Zhao Y, DiConcini D, Puxeddu E, Esen A, et al.2000 Androgen receptor mutations in prostate cancer. Cancer Research 60 944–949.
McPherson SJ, Ellem SJ, Simpson ER, Patchev V, Fritzemeier K-H & Risbridger GP 2007 Essential role for estrogen receptorβin stromal-epithelial regulation of prostatic hyperplasia. Endocrinology 148 566–574. (doi:10.1210/en.2006-0906)
McTernan P, Anwar A, Eggo M, Barnett A, Stewart P & Kumar S 2000 Gender differences in the regulation of P450 aromatase expression and activity in human adipose tissue. International Journal of Obesity 24 875–881. (doi:10.1038/sj.ijo.0801254)
Miftakhova R, Hedblom A, Semenas J, Robinson B, Simoulis A, Malm J, Rizvanov A, Heery DM, Mongan NP, Maitland NJ, et al.2016 Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow. Cancer Research 76 2453–2464. (doi:10.1158/0008-5472.CAN-15-2340)
Mo Z, Liu M, Yang F, Luo H, Li Z, Tu G & Yang G 2013 GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer. Breast Cancer Research 15 1–15.
Mohler JL, Gregory CW, Ford OH, Kim D, Weaver CM, Petrusz P, Wilson EM & French FS 2004 The androgen axis in recurrent prostate cancer. Clinical Cancer Research 10 440–448. (doi:10.1158/1078-0432.CCR-1146-03)
Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD & Nelson PS 2008 Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Research 68 4447–4454. (doi:10.1158/0008-5472.CAN-08-0249)
Montico F, Hetzl AC, Cândido EM & Cagnon VHA 2013 Angiogenic and tissue remodeling factors in the prostate of elderly rats submitted to hormonal replacement. Anatomical Record 296 1758–1767. (doi:10.1002/ar.22786)
Mueller JW, Gilligan LC, Idkowiak J, Arlt W & Foster PA 2015 The regulation of steroid action by sulfation and desulfation. Endocrine Reviews 36 526–563. (doi:10.1210/er.2015-1036)
Muir M, Romalo G, Wolf L, Elger W & Schweikert H-U 2004 Estrone sulfate is a major source of local estrogen formation in human bone. Journal of Clinical Endocrinology & Metabolism 89 4685–4692. (doi:10.1210/jc.2004-0049)
Murray R & Pitt P 1985 Treatment of advanced prostatic cancer, resistant to conventional therapy with aminoglutethimide. European Journal of Cancer and Clinical Oncology 21 453–458. (doi:10.1016/0277-5379(85)90036-7)
Nakamura Y, Suzuki T, Fukuda T, Ito A, Endo M, Moriya T, Arai Y & Sasano H 2006 Steroid sulfatase and estrogen sulfotransferase in human prostate cancer. Prostate 66 1005–1012. (doi:10.1002/pros.20426)
Nelson AW, Tilley WD, Neal DE & Carroll JS 2014 Estrogen receptor beta in prostate cancer: friend or foe? Endocrine-Related Cancer 21 T219–T234.
O’Dowd BF, Nguyen T, Marchese A, Cheng R, Lynch KR, Heng HHQ, Kolakowski Jr LF & George SR 1998 Discovery of three novel g-protein-coupled receptor genes. Genomics 47 310–313. (doi:10.1006/geno.1998.5095)
Oduwole OO, Mäkinen MJ, Isomaa VV, Pulkka A, Jernvall P, Karttunen TJ & Vihko PT 2003 17β-Hydroxysteroid dehydrogenase type 2: independent prognostic significance and evidence of estrogen protection in female patients with colon cancer. Journal of Steroid Biochemistry and Molecular Biology 87 133–140. (doi:10.1016/j.jsbmb.2003.08.008)
Parkin DM, Whelan SL, J F, L T & DB T 1997 Cancer Incidence in Five Continents. Lyon, France: International Agency for Research on Cancer Scientific Publications.
Parkin DM, Bray FI & Devesa SS 2001 Cancer burden in the year 2000. The global picture. European Journal of Cancer 37 (Supplement 8) 4–66. (doi:10.1016/S0959-8049(01)00267-2)
Piao Y-s, Wiesenfeld P, Sprando R & Arnold JT 2013 TGFβ1 alters androgenic metabolites and hydroxysteroid dehydrogenase enzyme expression in human prostate reactive stromal primary cells: Is steroid metabolism altered by prostate reactive stromal microenvironment? Journal of Steroid Biochemistry and Molecular Biology 138 206–213. (doi:10.1016/j.jsbmb.2013.1005.1016)
Pilšáková L, Riečanský I & Jagla F 2010 The physiological actions of isoflavone phytoestrogens. Physiological Research/Academia Scientiarum Bohemoslovaca 59 651–664.
Polari L, Yatkin E, Martínez Chacón MG, Ahotupa M, Smeds A, Strauss L, Zhang F, Poutanen M, Saarinen N & Mäkelä SI 2015 Weight gain and inflammation regulate aromatase expression in male adipose tissue, as evidenced by reporter gene activity. Molecular and Cellular Endocrinology 412 123–130. (doi:10.1016/j.mce.2015.06.002)
Prins GS & Hu W-Y 2013 Stem Cells and Prostate Cancer. New York, NY, USA: Springer New York.
Prins GS, Huang L, Birch L & Pu Y 2006 The role of estrogens in normal and abnormal development of the prostate gland. Annals of the New York Academy of Sciences 1089 1–13. (doi:10.1196/annals.1386.009)
Prossnitz ER, Arterburn JB & Sklar LA 2007 GPR30: a G protein-coupled receptor for estrogen. Molecular and Cellular Endocrinology 265–266 138–142. (doi:10.1016/j.mce.2006.12.010)
Prossnitz ER, Oprea TI, Sklar LA & Arterburn JB 2008a The ins and outs of GPR30: a transmembrane estrogen receptor. Journal of Steroid Biochemistry and Molecular Biology 109 350–353. (doi:10.1016/j.jsbmb.2008.03.006)
Prossnitz ER, Sklar LA, Oprea TI & Arterburn JB 2008b GPR30: a novel therapeutic target in estrogen-related disease. Trends in Pharmacological Sciences 29 116–123. (doi:10.1016/j.tips.2008.01.001)
Purohit A & Foster PA 2012 Steroid sulfatase inhibitors for estrogen- and androgen-dependent cancers. Journal of Endocrinology 212 99–110. (doi:10.1530/JOE-11-0266)
Quaresma M, Coleman MP & Rachet B 2015 40-year trends in an index of survival for all cancers combined and survival adjusted for age and sex for each cancer in England and Wales, 1971–2011: a population-based study. Lancet 385 1206–1218. (doi:10.1016/S0140-6736(14)61396-9)
Raftogianis R, Creveling C, Weinshilboum R & Weisz J 2000 Chapter 6: estrogen metabolism by conjugation. JNCI Monographs 2000 113–124. (doi:10.1093/oxfordjournals.jncimonographs.a024234)
Rago V, Romeo F, Giordano F, Ferraro A & Carpino A 2016 Identification of the G protein-coupled estrogen receptor (GPER) in human prostate: expression site of the estrogen receptor in the benign and neoplastic gland. Andrology 4 121–127. (doi:10.1111/andr.12131)
Rajfer J & Coffey DS 1978 Sex steroid imprinting of the immature prostate. Long-term effects. Investigative Urology 16 186–190.
Reed MJ, Purohit A, Woo LWL, Newman SP & Potter BVL 2005 Steroid sulfatase: molecular biology, regulation, and inhibition. Endocrine Reviews 26 171–202. (doi:10.1210/er.2004-0003)
Reger M, Zollinger T, Liu Z, Jones J & Zhang J 2015 Abstract 1884: dietary intake of phytoestrogens and the risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Research 75 1884.
Risbridger GP, Davis ID, Birrell SN & Tilley WD 2010 Breast and prostate cancer: more similar than different. Nature Reviews. Cancer 10 205–212. (doi:10.1038/nrc2795)
Robinson-Rechavi M, Garcia HE & Laudet V 2003 The nuclear receptor superfamily. Journal of Cell Science 116 585–586. (doi:10.1242/jcs.00247)
Romanel A, Tandefelt DG, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, Salvi S, Amadori D, Zafeiriou Z, Rescigno P, et al.2015 Plasma AR and abiraterone-resistant prostate cancer. Science Translational Medicine 7 312re310–312re310. (doi:10.1126/scitranslmed.aac9511)
de Ronde W, van der Schouw YT, Muller M, Grobbee DE, Gooren LJG, Pols HAP & de Jong FH 2005 Associations of sex-hormone-binding globulin (SHBG) with non-SHBG-bound levels of testosterone and estradiol in independently living men. Journal of Clinical Endocrinology & Metabolism 90 157–162. (doi:10.1210/jc.2004-0422)
Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, Brown GD, Gojis O, Ellis IO, Green AR, et al.2012 Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 481 389–393. (doi:10.1038/nature10730)
Roy J, Lefebvre J, Maltais R & Poirier D 2013 Inhibition of dehydroepiandosterone sulfate action in androgen-sensitive tissues by EM-1913, an inhibitor of steroid sulfatase. Molecular and Cellular Endocrinology 376 148–155. (doi:10.1016/j.mce.2013.06.022)
Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, et al.2013 Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine 368 138–148. (doi:10.1056/NEJMoa1209096)
Sakr WA, Haas GP, Cassin BF, Pontes JE & Crissman JD 1993 The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. Journal of Urology 150 379–385.
Samaras N, Frangos E, Forster A, Lang PO & Samaras D 2012 Andropause: a review of the definition and treatment. European Geriatric Medicine 3 368–373. (doi:10.1016/j.eurger.2012.08.007)
Santen RJ, Thibault A, Myers C & Chung L 1997 Meeting summary: workshop conference on endocrine therapy of advanced prostate cancer, airlie house, November 3–4, 1996. Urologic Oncology: Seminars and Original Investigations 3 31–38. (doi:10.1002/1097-0142(20011015)
Santen RJ, Petroni GR, Fisch MJ, Myers CE, Theodorescu D & Cohen RB 2001 Use of the aromatase inhibitor anastrozole in the treatment of patients with advanced prostate carcinoma. Cancer 92 2095–2101. (doi:10.1002/1097-0142(20011015)92:8<2095::aid-cncr1550>3.0.co;2-y)
Sarveswaran S, Gautam SC & Ghosh J 2012 Wedelolactone, a medicinal plant-derived coumestan, induces caspase-dependent apoptosis in prostate cancer cells via downregulation of PKCε without inhibiting Akt. International Journal of Oncology 41 2191–2199. (doi:10.3892/ijo.2012.1664)
Savoy RM & Ghosh PM 2013 The changing roles of steroid nuclear receptors with prostate cancer progression. Endocrine-Related Cancer 20 C9–C11. (doi:10.1530/ERC-13-0193)
Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, et al.2012 Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 367 1187–1197. (doi:10.1056/NEJMoa1207506)
Sharifi N & Auchus RJ 2012 Steroid biosynthesis and prostate cancer. Steroids 77 719–726. (doi:10.1016/j.steroids.2012.03.015)
Siegel R, Naishadham D & Jemal A 2012 Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62 10–29. (doi:10.3322/caac.20138)
Slavin S, Yeh C-R, Da J, Yu S, Miyamoto H, Messing EM, Guancial E & Yeh S 2014 Estrogen receptorαin cancer-associated fibroblasts suppresses prostate cancer invasion via modulation of thrombospondin 2 and matrix metalloproteinase 3. Carcinogenesis 35 1301–1309. (doi:10.1093/carcin/bgt488)
Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J & Kantoff PW 2002 Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer 95 1864–1868. (doi:10.1002/cncr.10844)
Stanway SJ, Purohit A, Woo LWL, Sufi S, Vigushin D, Ward R, Wilson RH, Stanczyk FZ, Dobbs N, Kulinskaya E, et al.2006 Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clinical Cancer Research 12 1585–1592. (doi:10.1158/1078-0432.CCR-05-1996)
Strom SS, Yamamura Y, Duphorne CM, Spitz MR, Babaian RJ, Pillow PC & Hursting SD 1999 Phytoestrogen intake and prostate cancer: a case‐control study using a new database. Nutrition and Cancer 33 20–25. (doi:10.1080/01635589909514743)
Szliszka E, Czuba ZP, Mertas A, Paradysz A & Krol W 2013 The dietary isoflavone biochanin-A sensitizes prostate cancer cells to TRAIL-induced apoptosis. Urologic Oncology: Seminars and Original Investigations 31 331–342.
Takeuchi S, Takahashi T, Sawada Y, Iida M, Matsuda T & Kojima H 2009 Comparative study on the nuclear hormone receptor activity of various phytochemicals and their metabolites by reporter gene assays using chinese hamster ovary cells. Biological and Pharmaceutical Bulletin 32 195–202. (doi:10.1248/bpb.32.195)
Takizawa I, Lawrence MG, Balanathan P, Rebello R, Pearson HB, Garg E, Pedersen J, Pouliot N, Nadon R, Watt MJ, et al.2015 Estrogen receptor alpha drives proliferation in PTEN-deficient prostate carcinoma by stimulating survival signaling, MYC expression and altering glucose sensitivity. Oncotarget 6 604–616. (doi:10.18632/oncotarget)
Taneja SS, Morton R, Barnette G, Sieber P, Hancock ML & Steiner M 2013 Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. Journal of Clinical Oncology 31 523–529. (doi:10.1200/JCO.2012.41.7634)
Taylor RA, Toivanen R, Frydenberg M, Pedersen J, Harewood L, Australian Prostate Cancer Bioresource, Collins AT, Maitland NJ & Risbridger GP 2012 Human epithelial basal cells are cells of origin of prostate cancer, independent of CD133 status. Stem Cells 30 1087–1096. (doi:10.1002/stem.1094)
Thomas P & Dong J 2006 Binding and activation of the seven-transmembrane estrogen receptor GPR30 by environmental estrogens: a potential novel mechanism of endocrine disruption. Journal of Steroid Biochemistry and Molecular Biology 102 175–179. (doi:10.1016/j.jsbmb.2006.09.017)
Usui T 2006 Pharmaceutical prospects of phytoestrogens. Endocrine Journal 53 7–20. (doi:10.1507/endocrj.53.7)
Utsumi T, Yoshimura N, Takeuchi S, Maruta M, Maeda K & Harada N 2000 Elevated steroid sulfatase expression in breast cancers. Journal of Steroid Biochemistry and Molecular Biology 73 141–145. (doi:10.1016/S0960-0760(00)00060-1)
Vidal AC, Howard LE, Moreira DM, Castro-Santamaria R, Andriole GL & Freedland SJ 2014 Obesity increases the risk for high-grade prostate cancer: results from the REDUCE study. Cancer Epidemiology, Biomarkers & Prevention 23 2936–2942.
Wang F, Vihma V, Soronen J, Turpeinen U, Hämäläinen E, Savolainen-Peltonen H, Mikkola TS, Naukkarinen J, Pietiläinen KH, Jauhiainen M, et al.2013 17β-Estradiol and estradiol fatty acyl esters and estrogen-converting enzyme expression in adipose tissue in obese men and women. Journal of Clinical Endocrinology & Metabolism 98 4923–4931. (doi:10.1210/jc.2013-2605)
Wernert N, Kern L, Heitz P, Bonkhoff H, Goebbels R, Seitz G, Inniger R, Remberger K & Dhom G 1990 Morphological and immunohistochemical investigations of the utriculus prostaticus from the fetal period up to adulthood. Prostate 17 19–30. (doi:10.1002/pros.2990170104)
White BA, Porterfield SP & Porterfield SP 2013 Endocrine and Reproductive Physiology. Philadelphia, PA, USA: Elsevier/Mosby.
Whittemore AS, Kolonel LN, Wu AH, John EM, Gallagher RP, Howe GR, Burch JD, Hankin J, Dreon DM, West DW, et al.1995 Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. Journal of the National Cancer Institute 87 652–661. (doi:10.1093/jnci/87.9.652)
Wright JL, Kwon EM, Ostrander EA, Montgomery RB, Lin DW, Vessella R, Stanford JL & Mostaghel EA 2011 Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes. Cancer Epidemiology Biomarkers & Prevention 20 619–627.
Yamnik RL & Holz MK 2010 mTOR/S6K1 and MAPK/RSK signaling pathways coordinately regulate estrogen receptorαserine 167 phosphorylation. FEBS Letters 584 124–128. (doi:10.1016/j.febslet.2009.11.041)
Yang M, Kenfield SA, Blarigan ELV, Kasperzyk JL, Sesso HD, Ma J, Stampfer M & Chavarro JE 2014 Abstract 1263: dietary patterns after prostate cancer diagnosis in relation to disease-specific and total mortality. Cancer Research 74 1263.
Yeh C-R, Da J,